Multivariate analysis of immunohistochemical evaluation of protein expression in pancreatic ductal adenocarcinoma reveals prognostic significance for persistent Smad4 expression only
- PMID: 22351431
- PMCID: PMC3306569
- DOI: 10.1007/s13402-012-0072-x
Multivariate analysis of immunohistochemical evaluation of protein expression in pancreatic ductal adenocarcinoma reveals prognostic significance for persistent Smad4 expression only
Abstract
Background: Pancreatic ductal adenocarcinoma (PDAC) has a dismal prognosis with a 5-year survival rate of <5% and an average survival of only 6 months. Although advances have been made in understanding the pathogenesis of PDAC in the last decades, overall survival has not changed. Various clinicopathological and immunohistological variables have been associated with survival time but the exact role that these variables play in relation to survival is not clear.
Methods and results: To examine how the variables affected survival independently, multivariate analysis was conducted in a study group of 78 pancreatic ductal adenocarcinomas. The analysis included clinicopathological parameters and protein expression examined by immunohistochemistry of p53, Smad4, Axl, ALDH, MSH2, MSH6, MLH1 and PMS2. Lymph node ratio <0.2 (p = 0.004), tumor free resection margins (p = 0.044) and Smad4 expression (p = 0.004) were the only independent prognostic variables in the multivariate analysis. Expression of the other proteins examined was not significantly related to survival.
Conclusions: Discrepancies with other studies in this regard are likely due to differences in quantification of immunohistochemical staining and the lack of multivariate analysis. It underscores the importance to standardize the methods used for the application of immunohistochemistry in prognostic studies.
Figures


Similar articles
-
Phosphatase PPM1A is a novel prognostic marker in pancreatic ductal adenocarcinoma.Hum Pathol. 2016 Sep;55:151-8. doi: 10.1016/j.humpath.2016.05.002. Epub 2016 May 16. Hum Pathol. 2016. PMID: 27195906
-
Immunohistochemically detected expression of 3 major genes (CDKN2A/p16, TP53, and SMAD4/DPC4) strongly predicts survival in patients with resectable pancreatic cancer.Ann Surg. 2013 Aug;258(2):336-46. doi: 10.1097/SLA.0b013e3182827a65. Ann Surg. 2013. PMID: 23470568
-
Genetic alterations of K-ras, p53, c-erbB-2, and DPC4 in pancreatic ductal adenocarcinoma and their correlation with patient survival.Pancreas. 2013 Mar;42(2):216-22. doi: 10.1097/MPA.0b013e31825b6ab0. Pancreas. 2013. PMID: 23344532
-
DPC4 gene expression in primary pancreatic ductal adenocarcinoma: relationship with CT characteristics.Br J Radiol. 2017 May;90(1073):20160403. doi: 10.1259/bjr.20160403. Epub 2017 Mar 24. Br J Radiol. 2017. PMID: 28339284 Free PMC article.
-
Well differentiation and intact Smad4 expression are specific features of groove pancreatic ductal adenocarcinomas.Pancreas. 2015 Apr;44(3):394-400. doi: 10.1097/MPA.0000000000000260. Pancreas. 2015. PMID: 25426619 Review.
Cited by
-
Diagnostic, Predictive and Prognostic Molecular Biomarkers in Pancreatic Cancer: An Overview for Clinicians.Cancers (Basel). 2021 Mar 3;13(5):1071. doi: 10.3390/cancers13051071. Cancers (Basel). 2021. PMID: 33802340 Free PMC article. Review.
-
An Algorithmic Immunohistochemical Approach to Define Tumor Type and Assign Site of Origin.Adv Anat Pathol. 2020 May;27(3):114-163. doi: 10.1097/PAP.0000000000000256. Adv Anat Pathol. 2020. PMID: 32205473 Free PMC article. Review.
-
Programmed Cell Death Ligand-1 (PD-L1) and CD8 Expression Profiling Identify an Immunologic Subtype of Pancreatic Ductal Adenocarcinomas with Favorable Survival.Cancer Immunol Res. 2019 Jun;7(6):886-895. doi: 10.1158/2326-6066.CIR-18-0822. Epub 2019 May 1. Cancer Immunol Res. 2019. PMID: 31043417 Free PMC article.
-
Intact SMAD-4 is a predictor of increased locoregional recurrence in upfront resected pancreas cancer receiving adjuvant therapy.J Gastrointest Oncol. 2021 Oct;12(5):2275-2286. doi: 10.21037/jgo-21-55. J Gastrointest Oncol. 2021. PMID: 34790392 Free PMC article.
-
Strategies for Increasing Pancreatic Tumor Immunogenicity.Clin Cancer Res. 2017 Apr 1;23(7):1656-1669. doi: 10.1158/1078-0432.CCR-16-2318. Clin Cancer Res. 2017. PMID: 28373364 Free PMC article. Review.
References
-
- Hsu CC, Herman JM, Corsini MM, Winter JM, Callister MD, Haddock MG, Cameron JL, Pawlik TM, Schulick RD, Wolfgang CL, Laheru DA, Farnell MB, Swartz MJ, Gunderson LL, Miller RC. Adjuvant chemoradiation for pancreatic adenocarcinoma: the Johns Hopkins Hospital-Mayo Clinic collaborative study. Ann Surg Oncol. 2010;17:981–90. doi: 10.1245/s10434-009-0743-7. - DOI - PMC - PubMed
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous